Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HCV-796 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Peg-Intron | DRUG | SC injection, weight based dosing, weekly, 48 weeks |
| REBETOL | DRUG | Capsules, weight based dosing, Q12 hrs daily, 48weeks |
| HCV 796 | DRUG | Capsules, 500 mg, Q 12 hrs. daily, 48 weeks |
| HCV-796 | DRUG | HCV-796 1000mg single dose |
Inclusion Criteria: * Infection with HCV genotype 1. * HCV- infected subjects naive to treatment. * HCV-infected non-responder subjects. Exclusion Criteria: * Women who are pregnant or breastfeeding. * ALT \>/ or = 5X the upper limit of normal. * AST \>/ or = 5X the upper limit of normal.
Top 1 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir |
HCV-796 is an investigational small molecule developed for the treatment of hepatitis C, a viral infection of the liver. It was studied in treatment-naive and non-responder patients with hepatitis C, as well as in subjects with liver disease. It is not an approved therapy and remains in clinical development.
HCV-796 was developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored both clinical trials of the compound, including a Phase 2 study in hepatitis C patients and a Phase 1 study in subjects with liver disease and healthy adults.
HCV-796 reached Phase 2 clinical development for hepatitis C. Both of its registered trials are completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA for any indication.
HCV-796 was studied in two completed trials. NCT00367887 was a Phase 2 study evaluating safety and clinical activity in treatment-naive and non-responder hepatitis C subjects, enrolling 246 patients in the United States and Puerto Rico. NCT00314054 was a Phase 1 safety study in 27 subjects with liver disease and healthy adults.
Yes, HCV-796 and HCV 796 refer to the same investigational compound. The hyphenated form HCV-796 is the standard spelling used in trial registrations and scientific literature, while HCV 796 is a common variant without the hyphen. Both names describe the same Pfizer hepatitis C candidate.
Across its two completed trials, HCV-796 enrolled a total of 273 participants. The Phase 2 study NCT00367887 accounted for 246 of those subjects, and the Phase 1 study NCT00314054 enrolled 27 subjects, including healthy adults and individuals with liver disease.